Work

OP0103 The effect of sirukumab plus methotrexate on circulating biomarkers of joint destruction in moderate to severe rheumatoid arthritis patients from the sirround-d phase 3 study

Year: 2017

Type: conference-abstract

Source: Annals of the Rheumatic Diseases

DOI: 10.1136/annrheumdis-2017-eular.3588

Authors: B Dasgupta, K Campbell, A-C Bay-Jensen, M Karsdal, K Sweet, M Sims, MJ Loza

Institutions: Janssen Research & Development (United States), Nordic Bioscience (Denmark), GlaxoSmithKline (United Kingdom)

Language: English

Topic: Rheumatoid Arthritis Research and Therapies

Subfield: Rheumatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

Funders: Amgen, Eli Lilly and Company, Pfizer, AstraZeneca, Sanofi, Biogen, F. Hoffmann-La Roche, Regeneron Pharmaceuticals, Celltrion, Genentech

OpenAlex ID: W2755714531

Cites:

Cited by: 1

Related to: 10